Merck's earnings call highlighted strong performance, especially in KEYTRUDA and GARDASIL, driving significant revenue growth.  Management expressed confidence in 2022 guidance and the company's long-term strategies, including molnupiravir, oncology expansion, and strategic acquisitions.  The call's positive tone and strong guidance suggest a positive short-term impact on the stock.

[1]
